We will further look into this and explore how we can help patients with addiction, potentially with GLP-1, Lange said, also adding that it has to be addressed in a scientific, and obviously also from a regulatory perspective, very rigorous way so we can really see the potential impact of GLP-1 in that space. However, in response to questions from Biospace, a Novo spokesperson said that Lange was referring to the already ongoing work studying semaglutide on liver damage and alcohol use in its phase 2 trial, and that the company has no plans to study the drug in broader addiction indications
Severe nausea leading to discontinuation of treatment occurred in a minority of participants
The short answer is no: combining these drugs is medically unsafe and can trigger severe side effects including uncontrolled blood sugar drops, extreme nausea, and heart rhythm problems
We identified three prior studies that, at the time, further suggested a possible link between GLP-1 and AUD